title: Platelet activation during plasma-reduced multicomponent PLT collection: a comparison between COBE Trima and Spectra LRS turbo cell separators.
abstract: BACKGROUND
  The wide diffusion of multicomponent collection in donor apheresis has led to the yielding of different components, such as plasma-reduced platelet-pheresis at high PLT concentration. We investigated whether this collection modality could induce more PLT activation compared to standard plateletpheresis.
  
  
  METHODS
  Forty-one plateletpheresis collections (20 Trima and 21 Spectra LRS Turbo v.7.0, COBE) were evaluated. Donor, procedure, and product data were recorded. ADP, collagen, and U46619 (a thromboxane-A2 analog)-induced PLT aggregation was investigated in basal (donor) and final (plateletpheresis unit) samples. The expression of PLT activation marker P-selectin (CD62P) was studied using flow cytometry in basal and final samples. In all cases, P-selectin was investigated in final samples after stimulation with ADP to assess for a possible further release of the antigen. Four additional plateletpheresis procedures were performed in donors from Group A, using the traditional, nonplasma-reduced program.
  
  
  RESULTS
  Plateletpheresis obtained by means of the Trima device showed a lower response to in-vitro induced PLT aggregation and a higher percentage of P-selectin-expressing PLT when compared to products obtained using the Spectra device. Moreover, P-selectin release after ADP stimulation was reduced in plateletpheresis units obtained using the Trima device. These differences disappeared when a nonplasma-reduced collection program was used. In-vivo evaluation did not detect any difference between plateletpheresis obtained by means of the two cell separators.
  
  
  CONCLUSIONS
  Plateletpheresis units obtained by means of multicomponent collection show a higher degree of PLT activation compared to traditional plateletpheresis procedures when high-concentration plasma-reduced products are collected. Randomized clinical studies are needed to assess the real impact of these findings in terms of in-vivo efficacy of plasma-reduced plateletpheresis units.
authors.affiliation: Clinical Pathology Department-Immunohematolgy Unit, University of Milanco-Biccoca-San Gerardo Hospital, Monza, Milan, Italy. p.perseghin@hsgerardo.org
authors.forename: Paolo
authors.initials: P
authors.lastname: Perseghin
authors.forename: Luca
authors.initials: L
authors.lastname: Mascaretti
authors.forename: Tiziana
authors.initials: T
authors.lastname: Speranza
authors.forename: Daniela
authors.initials: D
authors.lastname: Belotti
authors.forename: Valentina
authors.initials: V
authors.lastname: Baldini
authors.forename: Maria
authors.initials: M
authors.lastname: Dassi
authors.forename: Mariarosa
authors.initials: M
authors.lastname: Riva
authors.forename: Enrico Maria
authors.initials: EM
authors.lastname: Pogliani
authors.forename: Gianalfredo
authors.initials: G
authors.lastname: Sciorelli
mesh_terms: D000244:Adenosine Diphosphate / Q000494:pharmacology; D000328:Adult; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism; D005260:Female; D006402:Hematologic Diseases / Q000097:blood / Q000628:therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D019007:P-Selectin / Q000378:metabolism; D015539:Platelet Activation; D010974:Platelet Aggregation; D010976:Platelet Count; D017713:Platelet Transfusion; D010983:Plateletpheresis / Q000295:instrumentation*
chemical_list: D019007:P-Selectin; D000244:Adenosine Diphosphate